The discriminative effects of the κ-opioid hallucinogen salvinorin A in nonhuman primates: Dissociation from classic hallucinogen effects

Psychopharmacology

Volumn 210, Issue 2, 2010, Pages 253-262

  Butelman, E R ^a   Rus, Szymon ^a   Prisinzano, Thomas E ^b   Kreek, Mary Jeanne ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b UNIVERSITY OF KANSAS   (United States)

Author keywords

Dynorphin; Hallucinogen; Opioid; Salvia divinorum; Salvinorin A; opioid

Indexed keywords

KAPPA OPIATE RECEPTOR; SALVINORIN A; 3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; 4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 METHOXYBENZYL] N,N DIETHYLBENZAMIDE; BREMAZOCINE; FENTANYL; KETAMINE; KETANSERIN; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; PSILOCYBINE; PSYCHEDELIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASSOCIATION; CONTROLLED STUDY; DRUG DEPENDENCE; IN VIVO STUDY; INSTRUMENTAL CONDITIONING; MALE; NONHUMAN; PRIORITY JOURNAL; REINFORCEMENT; RHESUS MONKEY; SEROTONINERGIC TRANSMISSION; ANIMAL BEHAVIOR; DISCRIMINATION LEARNING; FACIAL EXPRESSION; PSYCHOPHARMACOLOGY; PTOSIS; STRUCTURE ANALYSIS;

ANIMALS; CONDITIONING, OPERANT; DISCRIMINATION (PSYCHOLOGY); DITERPENES, CLERODANE; DOSE-RESPONSE RELATIONSHIP, DRUG; HALLUCINOGENS; MACACA MULATTA; MALE; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU;

EID: 77953286927     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-009-1771-5     Document Type: Article

References (46)

1. Baker LE, Panos JJ, Killinger BA, Peet MM, Bell LM, Haliw LA, Walker SL (2009) Comparison of the discriminative stimulus effects of salvinorin A and its derivatives to U69, 593 and U50, 488 in rats. Psychopharmacology 203: 203-211
2. Brandt MR, Negus SS, Mello NK, Furness MS, Zhang X, Rice KC (1999) Discriminative stimulus effects of the nonpeptidic deltaopioid agonist SNC80 in rhesus monkeys. J Pharmacol Exp Ther 290: 1157-1164
3. Butelman ER, Harris TJ, Kreek MJ (1999) Effects of E-2078, a stable dynorphin A(1-8) analog, on sedation and serum prolactin levels in rhesus monkeys. Psychopharmacology (Berl) 147: 73-80
4. Butelman ER, Harris TJ, Kreek MJ (2004) The plant-derived hallucinogen, salvinorin A, produces kappa-opioid agonist-like discriminative effects in rhesus monkeys. Psychopharmacology 172: 220-224
5. Butelman ER, Mandau M, Tidgewell K, Prisinzano TE, Yuferov V, Kreek MJ (2007) Effects of salvinorin A, a kappa-opioid hallucinogen, on a neuroendocrine biomarker assay in nonhuman primates with high kappa-receptor homology to humans. J Pharmacol Exp Ther 320: 300-306
6. Butelman ER, Prisinzano TE, Deng H, Rus S, Kreek MJ (2008) Unconditioned behavioral effects of the powerful kappa-opioid hallucinogen salvinorin A in nonhuman primates: fast onset and entry into cerebrospinal fluid. J Pharmacol Exp Ther 328: 588-597, PMC2682281
7. Carey GJ, Bergman J (2001) Enadoline discrimination in squirrel monkeys: effects of opioid agonists and antagonists. J Pharmacol Exp Ther 297: 215-223
8. Castner SA, Goldman-Rakic PS (1999) Long-lasting psychotomimetic consequences of repeated low-dose amphetamine exposure in rhesus monkeys. Neuropsychopharmacology 20: 10-28
9. Castner SA, Goldman-Rakic PS (2003) Amphetamine sensitization of hallucinatory-like behaviors is dependent on prefrontal cortex in non-human primates. Biol Psychiatry 54: 105-110
10. Chavkin C, Sud S, Jin W, Stewart J, Zjawiony JK, Siebert DJ, Toth BA, Hufeisen SJ, Roth BL (2004) Salvinorin A, an active component of the halucinogenic sage Salvia divinorum, is a highly efficacious kappa opioid receptor agonist: Structural and functional considerations. J Pharmacol Exp Ther 308: 1197-1203
11. Chemik DA, Gilltags D, Laine H, Hendler J, Silver JM, Davidson AB, Schwam. EM, Siegel JL (1990) Validity and reliability of the Observer's Assessment of Alertness/Sedation Scale: study with intravenous midazolam. J Clin Psychopharmacol 10: 244-251
12. Condy C, Wattiez N, Rivaud-Pechoux S, Gaymard B (2005) Ketamine-induced distractability: an oculomotor study in monkeys. Biol Psychiatry 57: 366-372
13. Davis WM, Bedford. JA, Guinn MM, Hatoum HT, Waters IW, Wilson MC, Braude MC (1978) Acute toxicity and gross behavioral effects of amphetamine, four methoxyamphetamines, and mescaline in rodents, dogs and monkeys. Toxicol Appl Pharmacol 45: 49-62
14. Dykstra LA, Gmerek DE, Winger G, Woods JH (1987) Kappa opioids in rhesus monkeys. I. Diuresis, sedation, analgesia and discriminative stimulus effects. J Pharmacol Exp Ther 242: 413-420
15. Fantegrossi WE, Woods JH, Winger G (2004) Transient reinforcing effects of phenylisopropylamine and indolealkylamine hallucinogens in rhesus monkeys. Behav Pharmacol 15: 149-158
16. France CP, Morse WH (1989) Pharmacological characterization of supersensitivity to naltrexone in squirrel monkeys. J Pharmacol Exp Ther 250: 937-943
17. France CP, Medzihradsky F, Woods JH (1994) Comparison of .kappa opioids in rhesus monkeys: behavioral effects and receptor binding affinities. J Pharmacol Exp Ther 268: 47-58
18. Gerak LR, France CP (1996) Discriminative stimulus effects of nalbuphine in rhesus monkeys. J Pharmacol Exp Ther 276: 523-531
19. Gonzales D, Riba J, Bouso JC, Gomez-Jarabo G, Barbanoj MJ (2006) Pattern of use and subjective effects of Salvia divinorum among recreational users. Drug Alcohol Depend 85: 157-162
20. Griffin OH, Miller BL, Khey DN (2008) Legally high? Legal considerations of Salvia divinorum. J Psychoactive Drugs 40: 183-191
21. Hooker JM, Xu Y, Schiffer W, Shea C, Carter P, Fowler JS (2008) Pharmacokinetics of the potent hallucinogen, salvinorin A in primates parallels the rapid onset, short duration of effects in humans. Neuroimage 41: 1044-1050
22. Hooker JM, Munro TA, Beguin C, Alexoff D, Shea C, Xu Y, Cohen BM (2009) Salvinorin A and derivatives: protection from metabolism does not prolong short-term whole body residence. Neuropharmacology 57: 386-391
23. Hoover V, Marlowe DB, Patapis NS, Festinger DS, Forman RF (2007) Internet access to Salvia divinorum: implications for policy, prevention and treatment. J Subst Abuse Treat 35: 22-27
24. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE (2009) Smoking continues gradual decline among U.S. teens, smokeless tobacco threatens a comeback. www.monitoringthefuture.org. Press Release, 14 Dec 2009
25. Khey DN, Miller BL, Griffin OH (2008) Salvia divinorum use among a college student sample. J Drug Educ 38: 297-306
26. Ko MC, Butelman ER, Traynor JR, Woods JH (1998) Differentiation of kappa opioid agonist-induced antinociception by naltrexone apparent pA2 analysis in rhesus monkeys. J Pharmacol Exp Ther 285: 518-526
27. Koek W, Kleven MS, Colpaert FC (1995) Effects of the NMDA antagonist, dizocilpine, in various drug discriminations: characterization of intermediate levels of drug lever selection. Behav Pharmacol 6: 590-600
28. Kumar V, Guo D, Cassel JA, Daubert JD, DeHaven RN, DeHavenHudkins DL, Gauntner EK, Gottshall SL, Greiner SL, Koblish M, Little PJ, Mansson E, Maycock AL (2005) Synthesis and evaluation of novel peripherally restricted kappa-opioid receptor agonists. Bioorg Med Chem Lett 15: 1091-1095
29. Lange JE, Reed MB, Ketchie Croff JM, Clapp .TD (2008) College student use of Salvia divinorum. Drug Alcohol Depend 94: 263-266
30. Li JX, Rice KC, France CP (2008) Discriminative stimulus effects of 1-(2, 5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM) in rhesus monkeys. J Pharmacol Exp Ther 324: 827-833
31. Li JX, Rice KC, France CP (2009) Discriminative stimulus effects of 1-(2, 5-dimethoxy-4-methylphenyl)-2aminopropane (DOM) in rhesus monkeys: antagonism and apparent pA2 analyses. J Pharmacol Exp Ther 328: 976-981
32. Miner JR, Heegard W, Plummer D (2002) End-tidal carbon dioxide monitoring during procedural sedation. Acad Emerg Med 9: 275-280
33. Negus SS, Burke TF, Medzihradsky F, Woods JH (1993) Effects of opioid agonists selective for mu, kappa and delta opioid receptors on schedule-controlled responding in rhesus monkeys: antagonism by quadazocine. J Pharmacol Exp Ther 267: 896-903
34. Paglia-Boak A, Mann RE, Adlaf EM, Rehm J (2009) Drug use among Ontario students, 1977-2009: Highlights from the 2009 OSDUHS. Centre for Addiction and Mental Health, Toronto
35. Pfeiffer A, Brantl V, Herz A, Emrich HM (1986) Psychotomimesis mediated by kappa opiate receptors. Science 233: 774-776
36. Rose TE, Behm FM, Westman EC, Coleman RE (1999) Arterial nicotine kinetics during cigarette smoking and intravenous nicotine administration. Drug Alcohol Depend 56: 99-107
37. Roth BL, Baner K, Westkaemper R, Siebert D, Rice KC, Steinberg S, Ernsberger P, Rothman RB (2002) Salvinorin A: a potent naturally occuring nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci U S A 99: 11934-11939
38. Schmidt MD, Schmidt MS, Butelman ER, Harding WW, Tidgewell K, Murry DJ, Kreek MJ, Prisinzano TE (2005) Pharmacokinetics of the plant-derived hallucinogen salvinorin A in nonhuman primates. Synapse 58: 208-210, PMID: 16138318
39. Shaw JS, Carroll JA, Alcock P, Main BG (1989) ICI204448: a k-opioid agonist with limited access to the CNS. Br J Pharmacol 96: 986-992
40. Siebert DJ (1994) Salvia divinorum and salvinorin A: new pharmacologic findings. J Ethnopharmacol 43: 53-56
41. Substance Abuse and Mental Health Services Administration (2008) The NSDUH report: use of specific hallucinogens: 2006. Available online: www.oas.samsha.gov/2k8/hallucinogens.pdf
42. Tanda G, Munzar P, Goldberg SR (2000) Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. Nat Neurosci 3: 1073-1074
43. Ur E, Wright DM, Bouloux PM, Grossman A (1997) The effects of spiradoline (U-62066E), a kappa-opioid receptor agonist, on neuroendocrine function in man. Br J Pharmacol 120: 781-784
44. Wang Y, Tang K, Inan S, Siebert D, Holzgrabe U, Lee DYW, Huang P, Li JG, Cowan A, Liu-Chen LY (2004) Comparison of pharmacological activities of three distinct k-ligands (salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo. J Pharmacol Exp Ther 312: 220-230
45. Williams KL, Pakarinen ED, Woods JH (1999) Quadazocine decreases responding reinforced by ethanol, sucrose, and phencyclidine fluid deliveries in rhesus monkeys: comparison to naltrexone's effects. Psychopharmacology (Berl) 144: 316-322
46. Willmore-Fordham CB, Krall DM, McCurdy CR, Kinder DH (2007) The hallucinogen derived from Salvia divinorum, salvinorin A, has kappa-opioid agonist discriminative stimulus effects in rats. Neuropharmacology 53: 481-486